FDA commissioner Marty Makary’s pledge came after Hims & Hers launched a compounded version of Novo’s Wegovy pill.

President Donald Trump has unveiled his TrumpRx website, offering over 40 drugs at steeply discounted prices to cash-paying ...

The London Cancer Hub will act as a global centre for cancer research as the UK looks to maintain competitiveness in the life ...

Medicine prices are facing increasing pricing pressure—and early 2026 is one of the first notable periods where the list ...

Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.

Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting ...

Everest Medicines has signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific ...

After more than a year out in the cold, the programme’s reauthorisation is a boost for rare disease therapy developers.

PrimeGen US and DT Cloud Star Acquisition have entered a definitive merger agreement at an implied equity value of around $1.5bn.

Eisai will now take ownership of the Japanese rights to Henlius' differentiated anti-PD-1 therapy, Hetronifly (serplulimab).

The upcoming patent cliff, the impact of geopolitical and policy issues, and a changing deal environment were discussed at ...

Lilly anticipates revenue of between $80bn and $83bn in 2026 – a year that could see orforglipron enter the US market.